Skip to main content

Advertisement

SpringerLink
Log in

Treating Burkitt Lymphoma in Adults

  • B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Burkitt lymphoma is an uncommon form of aggressive lymphoma affecting approximately 1200 patients per year in the USA. It is characterized by a translocation involving the MYC oncogene. Three subtypes of Burkitt lymphoma are recognized: the endemic form, occurring primarily in Africa and associated with the Epstein-Barr virus (EBV); the sporadic form, representing less than 3 % of all non-Hodgkin lymphomas (NHL); and the immunodeficiency-associated form, occurring primarily in HIV-infected patients. Burkitt lymphoma appears histologically with a diffuse pattern of intermediate-sized monomorphic B cells, multiple nucleoli, a very high proliferative rate, and frequent mitotic figures. Recent advances in transcriptional profiling have improved the current molecular understanding of Burkitt lymphoma and have better characterized its mutational landscape. Most Burkitt lymphoma patients are cured with intensive treatment; however, prognosis is poor in elderly patients and those with relapsed disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. O’Conor GT, Davies JN. Malignant tumors in African children. With special reference to malignant lymphoma. J Pediatr. 1960;56:526–35.

    Article  PubMed  Google Scholar 

  2. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1:702–3.

    Article  CAS  PubMed  Google Scholar 

  3. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E. Burkitt’s lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci. 2007;7:166–75.

    PubMed Central  PubMed  Google Scholar 

  4. Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. 2012;156:744–56.

    Article  CAS  PubMed  Google Scholar 

  5. de-The G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Ugandan prospective study. Nature. 1978;274:756–61.

  6. Geser A, Brubaker G, Draper CC. Effect of a malaria suppression program on the incidence of African Burkitt’s lymphoma. Am J Epidemiol. 1989;129:740–52.

    CAS  PubMed  Google Scholar 

  7. Torgbor C, Awuah P, Deitsch K, Kalantari P, Duca KA, Thorley-Lawson DA. A multifactorial role for P. falciparum malaria in endemic Burkitt’s lymphoma pathogenesis. PLoS Path. 2014;10:e1004170.

  8. Kalter SP, Riggs SA, Cabanillas F, et al. Aggressive non-Hodgkin’s lymphomas in immunocompromised homosexual males. Blood. 1985;66:655–9.

    CAS  PubMed  Google Scholar 

  9. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973–2005. Int J Canc J Int Canc. 2010;126:1732–9.

    CAS  Google Scholar 

  11. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.

    Article  CAS  PubMed  Google Scholar 

  12. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.

    Article  CAS  PubMed  Google Scholar 

  13. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44:1321–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44:1316–20.

    Article  CAS  PubMed  Google Scholar 

  15. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116–20. This paper highlights novel methods of high throughput sequencing to reveal novel mutations contributing to BL pathogenesis” suggesting opportunities to improve therapy for patients with BL.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Nakamura N, Nakamine H, Tamaru J, et al. The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. Modern Pathol Offic J United States Can Acad Pathol Inc. 2002;15:771–6.

    Article  Google Scholar 

  17. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol Offic J Am Soc Clin Oncol. 2014;32:3059–68.

    Article  Google Scholar 

  18. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol Offic J Am Soc Clin Oncol. 1996;14:925–34.

    CAS  Google Scholar 

  19. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004;100:1438–48.

    Article  CAS  PubMed  Google Scholar 

  20. Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995;85:664–74.

    CAS  PubMed  Google Scholar 

  21. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 Study. Annal Oncol Offic J Eur Soc Med Oncol / ESMO. 2002;13:1264–74.

    Article  CAS  Google Scholar 

  22. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112:2248–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol. 2011;22:1859–64.

    Article  CAS  PubMed  Google Scholar 

  24. Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma. Br J Haematol. 2012;156:234–44.

    Article  CAS  PubMed  Google Scholar 

  25. Evens AM, Carson KR, Kolesar J, et al. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt’s lymphoma. Ann Oncol. 2013;24:3076–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915–25. This very important paper demonstrates that with lower intensity infusional chemotherapy, patients with BL have excellent outcomes with manageable toxicity. This paper also deals with CNS prophylaxis as well as addressing CNS involvement of BL patients.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol Offic J Am Soc Clin Oncol. 1999;17:2461–70.

    CAS  Google Scholar 

  28. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–80.

    Article  CAS  PubMed  Google Scholar 

  29. Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B Study 10 002. Br J Haematol. 2014;165:102–11. This large study demonstrated that a brief but highly intense chemotherapy program is feasible and effective in a multicenter setting.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma—outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol Offic J Am Soc Clin Oncol. 1996;14:2465–72.

    CAS  Google Scholar 

  31. Song KW, Barnett MJ, Gascoyne RD, et al. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol. 2006;133:634–7.

    Article  PubMed  Google Scholar 

  32. Hoffmann C, Wolf E, Wyen C, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma. 2006;47:1872–80.

    Article  PubMed  Google Scholar 

  33. Ribera JM, Garcia O, Grande C, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013;119:1660–8.

    Article  CAS  PubMed  Google Scholar 

  34. Kelly JL, Toothaker SR, Ciminello L, et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009;9:307–10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene. 2014;33:2928–37.

    Article  CAS  PubMed  Google Scholar 

  36. Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011;108:16669–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Tan Y, Sementino E, Pei J, Kadariya Y, Ito TK, Testa JR. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. Cancer Biol Ther. 2015;16(4):580-8. doi: 10.1080/15384047.2015.1018495.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA

    Carla Casulo & Jonathan Friedberg

Authors
  1. Carla Casulo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Friedberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carla Casulo.

Additional information

This article is part of the Topical Collection on B-cell NHL, T-cell NHL, and Hodgkin Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Casulo, C., Friedberg, J. Treating Burkitt Lymphoma in Adults. Curr Hematol Malig Rep 10, 266–271 (2015). https://doi.org/10.1007/s11899-015-0263-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-015-0263-4

Keywords

Search

Navigation